Gilead Sciences’ blockbuster antibody-drug conjugate Trodelvy has encountered some clinical speed bumps in 2024 in bladder and lung cancer. Still, analysts remain bullish on its prospects in the oncology space.
Gilead’s Trodelvy Stumbles in Late-Stage Trials But Remains Prized Cancer Asset Read More »
La presentación temprana puede tener síntomas inespecíficos
A partir de un caso clínico | Apendicitis: una revisión rápida Read More »
El tratamiento dietético es más eficaz que los medicamentos en el SII
Tratamientos dietéticos vs farmacológicos | Síndrome del intestino irritable Read More »
El mecanismo puede estar relacionado con factores genéticos, secreción anormal de hormonas, lesión por estrés oxidativo, hiperinsulinemia y aumento de la producción de factores inflamatorios.
Correlación y prevención clínica | Diabetes mellitus y cáncer de tiroides Read More »
Bacteriemia de presunta fuente urinaria en adultos hospitalizados con bacteriuria asintomática
¿Tratar o no tratar? | Bacteriuria asintomática en adultos hospitalizados Read More »
The court’s controversial decision raises the bar for healthcare regulators when they’re implementing laws with undefined terms — and opens the door for stakeholders in the industry to sue when they’re unhappy with an agency’s reading of statute.
SCOTUS strikes down Chevron doctrine, curbing federal agency power Read More »
The telehealth vendor’s stock price has declined significantly since 2020. It received a warning this spring that its stock was trading below minimum standards, and could be removed from trading.
Amwell to implement reverse stock split to avoid delisting Read More »
The agency said which trials need diversity action plans and presented the timeline for implementing the requirement.
FDA shares draft guidance on clinical trial diversity action plans Read More »
The UnitedHealth pharmacy benefit manager did not have to admit guilt as part of the settlement, which amounts to a minuscule fraction of its annual revenue.
Optum Rx reaches $20M settlement with Justice Department over opioid prescribing Read More »
Steward has been gunning for the deal since March. Without Optum at the table, it’s unclear who will buy the struggling health system’s medical clinics.
Optum backs out of deal to buy Steward’s physician group Read More »
